Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy Evaluation of IM19 CAR-T Cells On CD19+ Refractory or Relapsed B-ALL Patients

Trial Profile

Safety and Efficacy Evaluation of IM19 CAR-T Cells On CD19+ Refractory or Relapsed B-ALL Patients

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs IM19 chimeric antigen receptor T cell theray Beijing Immunochina Medical Science and Technology (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B-cell leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Sponsors Beijing Immunochina Medical Science and Technology
  • Most Recent Events

    • 04 Dec 2018 Results assessing the safety and efficacy in subgroup of patients with EMD, High Leukemia Burden (HLB), TP53 mutation, BCR-ABL (+) mutation, or post-allo-HSCT, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 31 Aug 2018 Biomarkers information updated
    • 06 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top